New Tools for the Urologist in the Management of Patients with Bone Metastases
|
|
- Catherine King
- 5 years ago
- Views:
Transcription
1 european urology supplements 6 (2007) available at journal homepage: New Tools for the Urologist in the Management of Patients with Bone Metastases Bob Djavan * Department of Urology, University Hospital Vienna, AKH, Urologie, Ebene 8D, Währinger Gürtel 18 20, 1090 Vienna, Austria Article info Keywords: Androgen-deprivation therapy Bone metastases Bone scan Prostate cancer Prostate-specific antigen Abstract Objectives: Bone metastases are common among patients with hormone-refractory prostate cancer and advanced renal cell carcinoma. Moreover, androgen-deprivation therapy (ADT) in patients with early prostate cancer has been associated with bone loss. Current guidelines for monitoring and managing bone health in patients with prostate cancer are evolving to optimize patient screening and treatment. Methods: Medline keyword searches and reviews of presentations from recent international symposia were performed to identify new tools for screening for bone metastases. In addition, guidelines and consensus recommendations were reviewed to identify bone health issues and their management in patients with genitourinary cancers. Results: Malignant bone disease contributes heavily to the burden of disease in patients with advanced prostate cancer. Furthermore, fractures are associated with decreased survival. The introduction of zoledronic acid has extended the skeletal health benefits of bisphosphonate therapy to the genitourinary cancer setting. Diagnosis of bone metastases while patients are still asymptomatic could allow the initiation of therapy before skeletal complications occur, thereby possibly delaying their onset. Recent analyses have identified risk factors for metastasis to bone, allowing urologists to better mobilize potentially limited resources for bone scans in their clinics. Moreover, algorithms for monitoring and treating bone loss in patients undergoing ADT may allow early detection and treatment of bone mineral density declines, thereby preserving patients functional independence throughout the continuum of care. Conclusions: The introduction of zoledronic acid and updated monitoring and treatment algorithms may aid in the maintenance of bone health in patients with genitourinary cancers. # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Tel /2615; Fax: address: bdjavan@hotmail.com /$ see front matter # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eursup
2 690 european urology supplements 6 (2007) New tools for the urologist in the management of patients with bone metastases Monitoring and treating patients during androgendeprivation therapy (ADT) after initial treatment with curative intent poses several challenges to the treating urologist. Maintenance of bone health during ADT is an emerging concern. Although the optimal detection methodologies for recurrent disease and implementation of additional therapies have yet to be established, it is becoming increasingly apparent that early detection and treatment of bone loss and bone metastases may be feasible and beneficial [1]. It is now recognized that patients receiving ADT may experience a progressive decrease in bone mineral density (BMD) that results in an increased risk of fractures [2 6] (Fig. 1 [6]). Recommendations from multidisciplinary expert panels have outlined monitoring strategies for BMD loss during ADT [7 9], which may allow optimal utilization of limited resources such as dual-energy X-ray absorptiometry scanning (Fig. 2 [7]). However, there is currently no consensus on the optimal therapeutic approach for patients who experience ADT-associated bone loss. Behavioral modification and dietary supplementation are important first steps for all patients experiencing bone loss, but these measures alone may not be sufficient to maintain BMD in some patients undergoing ADT [7], and antiresorptive therapy with bisphosphonates may be needed to preserve bone health. Currently there is no consensus on optimal treatment selection; however, among bisphosphonates tested, zoledronic acid (4 mg via 15-min infusion) has demonstrated the most consistent efficacy, not only preventing bone loss but also substantially increasing BMD above baseline values in multiple clinical trials in patients receiving ADT for nonmetastatic prostate cancer or prostate cancer with bone metastases [9 11]. Moreover, the increased bone metabolism associated with ADT has also been associated with an increased risk of metastasis to bone in an animal model, and treatment with zoledronic acid significantly reduced bone metabolism and the incidence of bone metastasis in this setting [12]. A clinical study is currently under way to explore whether early use of zoledronic acid can prevent metastasis to bone in patients with prostate cancer (as discussed by Dr Petrylak on pages ). Results from this study are eagerly awaited, especially in light of recent data from a pilot study [13] in patients with high-risk solid tumors (N = 40) wherein zoledronic acid significantly prolonged bone metastasis-free survival compared with placebo ( p < ; Fig. 3). The widespread availability of prostate-specific antigen (PSA) testing has allowed the detection of recurrent disease while it is still at an asymptomatic stage. Locating the site of recurrence, however, may be challenging. In addition to the absolute PSA value, assessment of PSA kinetics is becoming a widely recognized tool [14,15]. For example, slow and linear increases in PSA levels suggest that disease recurrence is localized, whereas rapid and exponential kinetics suggest that metastasis has occurred [16]. Metastasis to bone is relatively common among patients whose PSA levels increase beyond 10 ng/ml or show rapid kinetics after initial treatment with curative intent [17]. On the basis of this and other recent studies, the current guidelines from the European Association of Urology recommend screening for metastatic disease be performed in patients with biochemical relapse if their PSA levels are >20 ng/ml, their PSA velocity is >20 ng/ml/yr, or if they have any symptoms of metastatic disease Fig. 1 Patients with prostate cancer (PC) undergoing androgen-deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist have an increased risk of bone fractures. Data from Smith MR et al [6].
3 european urology supplements 6 (2007) Fig. 2 Guidance from an expert panel for bone health monitoring and treatment during androgen-deprivation therapy. * Rule out pathologic fracture from bone metastases. ADT: androgen-deprivation therapy; BMD: bone mineral density; DEXA: dual-energy X-ray absorptiometry; CT: computed tomography. Adapted with permission from Diamond TH et al [7]. [18]. However, use of these PSA cut-off values may lead to underdiagnosis of bone metastases, especially in the case of PSA-negative relapse, which typically has a greater osteolytic component compared with PSA-expressing tumors [19]. Indeed, a small retrospective evaluation reported that bisphosphonate treatment in patients with PSAnegative recurrent disease not only reduced pain but also produced a radiographic response in the bone lesions [20]. The introduction of metabolic-labeling agents such as 11 C-acetate (AC) and image fusion technologies may provide imaging specialists with sensitive tools for the detection of visceral metastases [21]. Fig. 3 Zoledronic acid prolonged bone metastasis-free survival (BMFS) in a pilot study in patients with high-risk solid tumors. Adapted with permission from Mystakidou Ketal[13]. Such imaging technologies have increased the sensitivity of screening for recurrent tumors throughout the body. However, traditional bone scans remain a sensitive and reliable method for the detection of sites of possible metastasis on the skeleton [18,21]. Furthermore, bone scans are relatively inexpensive compared with the emerging methodologies for the detection of visceral metastases. In prostate cancer, as with other solid tumors, the skeleton is the most common target site for tumor metastasis [22]. Prostate cancer appears to have a predilection for metastasizing to bone, especially in the lumbar spine [23], which may place patients at risk for painful and potentially debilitating spinal cord compression [24]. Therefore, bone scans could be a first step in screening for metastatic disease in patients with rising PSA levels after initial radical prostatectomy. Moreover, levels of biochemical markers of bone metabolism are often perturbed in patients with malignant bone disease [25 28], and bone marker assessment may one day assist in the early identification and monitoring of bone metastases. Bisphosphonates have become an integral component of therapy for patients with bone lesions from multiple myeloma or breast cancer [29], but early-generation bisphosphonates demonstrated limited efficacy in patients with bone metastases from genitourinary malignancies [1]. Within the past 5 yr, the new-generation bisphosphonate zoledronic acid has demonstrated efficacy in the prevention of skeletal morbidity in patients with bone metastases secondary to solid tumors other than breast cancer, and has received international
4 692 european urology supplements 6 (2007) Table 1 Recommendations from a multidisciplinary expert panel on the use of bisphosphonates in patients with prostate cancer Patient s condition Bone scan negative * in hormone-sensitive patients Bone scan negative * in hormone-refractory patients Bone scan positive * in hormone-sensitive patients Bone scan positive * in hormone-refractory patients IV bisphosphonate No Use of bisphosphonate at physician s discretion; monitor patient closely IV bisphosphonate therapy should be strongly considered Yes * At any point that the patient has bone loss, consider a bisphosphonate. IV: intravenous. Adapted with permission from Carroll PR et al [37]. regulatory approval for the treatment of bone metastases secondary to a broad range of solid tumors [30 34], thereby extending the benefits of bisphosphonate therapy to patients with hormonerefractory prostate cancer (HRPC) and other genitourinary tumors. On radiographs bone metastases can appear osteoblastic (characterized by increased bone formation; typical of metastases secondary to prostate cancer), osteolytic (characterized by increased bone resorption; typical of metastases secondary to renal cell carcinoma [RCC]), or mixed (typical of bone metastases from other solid tumors) in appearance, but all malignant bone disease is associated with increases in osteolytic bone destruction and increased risk of skeletal-related events (SREs) [22]. These complications include pathologic fracture, severe bone pain requiring palliative radiotherapy (external beam or radiopharmaceuticals) or palliative change in the chemotherapeutic regimen (for patients with HRPC), the requirement for orthopedic surgery to bone, and spinal cord compression [30]. Osteolytic disease is also associated with hypercalcemia of malignancy, a potentially life-threatening event [22]. Zoledronic acid (4 mg via 15-min infusion every 3 wk for up to 2 yr) significantly delayed the onset of SREs and reduced the ongoing risk of SREs in randomized placebocontrolled trials in patients with bone metastases from HRPC, and in patients with bone metastases from lung cancer and other solid tumors, including RCC ( p < 0.05) [30 34]. Use of bisphosphonates has been widely recommended for patients with bone metastases from prostate cancer [18,35 37], and the utility of bisphosphonates throughout the disease continuum has been reviewed (Table 1 [37]). However, many of the patients who enrolled in the zoledronic acid phase 3 studies had already experienced potentially disabling SREs. Detection and treatment of bone metastases before the onset of SREs could therefore slow the erosion in quality of life and functional independence that may occur in patients with advanced cancer. Indeed, exploratory analyses suggest that earlier treatment of bone metastases before the onset of bone pain or SREs may even be more efficacious than later treatment in reducing the incidence of SREs (as discussed by Dr Saad on pages ). In the past, treatment of bone metastases was viewed as mainly palliative therapy. Recent evidence, however, suggests that the extent of bone metastases and skeletal morbidity may play an important role in the disease course [22,38 40]. In a correlative study [38] in patients with bone metastases from HRPC (N = 56), the percentage of the skeletal surface area that was affected by metastatic bone disease was the only significant covariate for decreased survival (risk ratio = 2.6 for patients with >4.6% of their skeleton affected versus patients with <4.6% of their skeleton affected; p = 0.016); and survival curves reflected sustained differences in survival during 4 yr of observation (Fig. 4). Furthermore, although no causal relationship has been established, in two separate retrospective analyses Fig. 4 Percentage of the skeleton affected by bone disease (<4.6% or >4.6%) inversely correlates with survival in patients with prostate cancer. Adapted with permission from Macmillan Publishers Ltd: Noguchi M et al. Br J Cancer 2003;88: , copyright 2003 [38].
5 european urology supplements 6 (2007) in patients with prostate cancer (N = 195 [39] and N = 643 [40]), patients with fractures had significantly decreased survival compared with patients who did not experience fractures ( p < 0.05). Further objective evidence for effects of bone-directed therapy on the disease course comes from an analysis of the RCC subset of the study in patients with bone metastases from lung cancer and other solid tumors, wherein 4 mg zoledronic acid significantly delayed the time to disease progression in bone compared with placebo [34]. These observations suggest that the interactions between tumor and bone can profoundly influence bone lesion progression, and the effects of bisphosphonates on malignant osteolysis can have meaningful effects. Therefore, earlier treatment may have benefits in addition to the preservation of physical functioning. 2. Conclusions With new diagnostic insights and the widespread availability of zoledronic acid, urologists are now equipped with multiple tools to aid in the maintenance of bone health in patients with genitourinary cancers. Ongoing clinical trials are investigating the use of biochemical markers of bone turnover in monitoring disease progression and response to therapy, the optimal timing and schedule of bisphosphonate therapy throughout the disease course in patients with prostate cancer and RCC, and whether use of zoledronic acid in patients with high-risk disease may reduce the risk of metastasis to bone. Authorship Dr. Djavan was responsible for the generation of this article, controlling the content from its inception, and gave final approval of the submitted version. ProEd Communications, Inc provided medical editorial assistance. Conflicts of interest Dr. Djavan has no potential conflicts of interest. Role of the funding source This article was supported by an unrestricted educational grant provided by Novartis Pharmaceuticals Corporation. Acknowledgements Funding for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. I thank Catherine Browning, PhD, ProEd Communications, Inc, for her medical editorial assistance with this manuscript. References [1] Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006;4: [2] Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90: [3] Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004;101: [4] Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352: [5] Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006;175: , discussion [6] Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136 9, discussion 139. [7] Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100: [8] Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003;20: [9] Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177: [10] Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972 8, discussion 978. [11] Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005;66: [12] Padalecki SS, Carreon M, Grubbs B, Cui Y, Guise TA. Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid. Oncology 2003;17(Suppl 3):32. [13] Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic
6 694 european urology supplements 6 (2007) acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22: [14] Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostatespecific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11: [15] Dotan ZA, Bianco Jr FJ, Rabbani F, et al. Pattern of prostatespecific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23: [16] Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43: [17] Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: [18] Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48: [19] Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels <10 ng/ml: the PSA negative patients. Cancer 2003;98: [20] Mystakidou K, Katsouda E, Parpa E, Vlahos L. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. J Pain Palliat Care Pharmacother 2005;19:41 5. [21] Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006;24: [22] Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s 9s. [23] Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31: [24] Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer 2003;2: [25] Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003;61: [26] Kataoka A, Yuasa T, Kageyama S, et al. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol) 2006;18: [27] Fukumitsu N, Uchiyama M, Mori Y, Kishimoto K, Nakada J. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients. Ann Nucl Med 2003;17: [28] Koizumi M, Yonese J, Fukui I, Ogata E. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 2002;167: [29] Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9(Suppl 4): [30] Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94: [31] Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96: [32] Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100: [33] Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21: [34] Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98: [35] The Royal College of Urologists Clinical Oncology Information Network. British Association of Urological Surgeons. Guidelines on the management of prostate cancer. Clin Oncol (R Coll Radiol) 1999;11:S [36] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. V Available at gls/pdf/prostate.pdf. Accessed January 22, [37] Carroll PR, Altwein J, Brawley O, et al. Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S, et al., editors. Prostate cancer: third international consultation on prostate cancer. Paris: Health Publications; p [38] Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 2003;88: [39] Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168: [40] Saad F, Coleman RE, Cook R, et al. Predictors of clinical outcome in patients with bone metastases from prostate cancer. J Clin Oncol 2006;24(Suppl):230s (abstract no. 4555).
HOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationDevelopment and Complications of Bone Metastases in Men With Prostate Cancer
Development and Complications of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationZoledronic acid in the management of metastatic bone disease
REVIEW Zoledronic acid in the management of metastatic bone disease Thomas J Polascik Vladimir Mouraviev Duke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC,
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationSerial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression
european urology 52 (2007) 1381 1387 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationA Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer
Yonsei Med J 48(6):1001-1008, 2007 DOI 10.3349/ymj.2007.48.6.1001 A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer Sung Joon Hong, 1 Kang
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationKey Words. Biologic markers Breast neoplasms Survival rate Zoledronic acid
The Oncologist Breast Cancer Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity ALLAN LIPTON, a RICHARD J. COOK, b PIERRE MAJOR, c MATTHEW
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationManaging Bone Pain in Metastatic Disease. Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018
Managing Bone Pain in Metastatic Disease Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018 None Disclosures Managing Bone Pain in Metastatic Disease This lecture will
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationCommunity care of Prostate Cancer. Shaun Costello Southern Cancer Network
Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3
More informationThe relationship between daily calcium intake and bone mineral density in men with prostate cancer
Original Article DAILY CALCIUM INTAKE AND BONE MINERAL DENSITY IN PROSTATE CANCER PLANAS ET AL. The relationship between daily calcium intake and bone mineral density in men with prostate cancer Jacques
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationZoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion
36 Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion Lee S. Rosen, M.D. 1 David H. Gordon, M.D. 2 William
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationFrancesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
More informationName of Policy: Cellular Immunotherapy for Prostate Cancer
Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationOncologist. The. Academia Pharma Intersect: Symptom Management and Supportive Care
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases MATTI AAPRO, a FRED SAAD, b LUIS
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationbone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER
bone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER IF YOU VE BEEN DIAGNOSED WITH METASTATIC BREAST CANCER (ALSO KNOWN AS STAGE IV BREAST CANCER),
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage
More informationAdvances in the Therapy of Prostate Cancer Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways
EUROPEAN UROLOGY SUPPLEMENTS 8 (2009) 747 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Advances in the Therapy of Prostate Cancer Induced Bone Disease: Current Insights
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More information17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom
My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate
More informationChallenges in the management of metastatic prostate cancer
Oncology 323 Challenges in the management of metastatic prostate cancer A significant number of men with prostate cancer will be elderly. Although some of the issues they face will be the same as their
More informationReview Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 941310, 6 pages doi:10.4061/2011/941310 Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationImaging of bone metastases
Imaging of bone metastases Antoine Feydy Service de Radiologie B Hôpital Cochin APHP Université Paris Descartes antoine.feydy@aphp.fr MEXICO 2016 INTRODUCTION Diagnostic Imaging Imaging Modalities Strengths,
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationMetastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid
REVIEW Metastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid Vera Hirsh Departments of Medicine and Oncology, McGill University Health Centre, Royal
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationBody composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study
Critical Reviews in Oncology/Hematology 68 (2008) 172 177 Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study Gijsberta J. van Londen a,, Matthew
More informationManagement of Acute Oncological emergencies
Management of Acute Oncological emergencies Malignant Spinal cord compression (MSCC) Neutropenic sepsis Superior vena caval obstruction Hypercalcemia Hyponatremia Bowel obstruction Brain Metastasis with
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationSkeletal complications of ADT: disease burden and treatment options
(2012) 14, 670 675 ß 2012 AJA, SIMM & SJTU. All rights reserved 1008-682X/12 $32.00 www.nature.com/aja REVIEW Skeletal complications of ADT: disease burden and treatment options Jacques Planas Morin and
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationSetting The study setting was secondary care. The economic study was undertaken in Spain.
Zoledronic acid versus pamidronate: cost minimisation in bone metastasis Slof J, Badia X, Lizan L, Bautista F J, Echarri E, Hurle A D, Pla R, Mangues M A, Rodriguez-Sasiain J M, Wood M A Record Status
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationMinimally Invasive Radiofrequency Ablation Treatment of Metastatic Spinal Tumors
Minimally Invasive Radiofrequency Ablation Treatment of Metastatic Spinal Tumors 1 Objectives Demographics of spinal tumors Treatment options and goals Adoption of RF ablation for pain palliation by NCCN
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More information05/12/2013. Philippa Aslet Senior Urology Nurse Specialist Hampshire Hospitals Foundation Trust
Philippa Aslet Senior Urology Nurse Specialist Hampshire Hospitals Foundation Trust Role of the Nurse Specialist Side Effects of Hormone manipulation Effects on Bone Health Catheter Management Nurses play
More informationGuidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer
Peterborough City Hospital Department of Urology Guidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer Hormonal Therapy - How does it work? Prostate Cancer relies on the presence
More information